Clinical Trial Update: Evaluate the Efficacy and Safety of Probiotic 6600 as an Adjuvant Therapy for Colitis [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 clinical trial is evaluating probiotic 6600 as an adjuvant therapy for colitis in inflammatory bowel disease, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colitis
• Inflammatory Bowel Disease

Drugs mentioned

• Probiotic 6600

Snippet

Sponsor: Changhai Hospital | Conditions: Colitis, IBD (Inflammatory Bowel Disease) | Phase 2, Phase 3 | Status: RECRUITING